Retrospective study on the treatment of patients with primary immune thrombocytopenia with atrepopa
Objective To investigate the retrospective study of the treatment of primary immune thrombocytopenia(ITP)with Aitracopol.Methods Medical records of 90 patients with ITP who received treatment in our hospital from October 2018 to February 2022 were retrospectively analyzed and grouped according to different treatment methods,with an average n=45.Dexamethasone group was treated with dexamethasone group,and itrepopopa group was treated with dexamethasone group and itrepopopa group combined with dexamethasone group,all n=45.The immune function,therapeutic effect and adverse reactions were compared.Results At 4 weeks after treatment,the levels of interleukin(IL)-2 and interferon(INF)-γ in the Altropopar group and dexamethasone group were lower than before treatment,and the levels of IL-4 in the Altropopar group and dexamethasone group were higher than before treatment.Aitripopal group was higher than dexamethasone group(P<0.05);At 4 weeks after treatment,the proportions of platelet(PLT)≥30×109/L were 68.89%and 40.00%in the Altropopar group and dexamethasone group,and the proportions of PLT≥50×109/L were 55.55%and 20.00%,respectively.The proportions in the Altropopar group were higher than those in the dexamethasone group(P<0.05).The proportions of PLT≥50×109/L in the half time and dexamethasone groups were 66.67%and 33.33%,respectively,and the proportions of PLT≥50×109/L for at least one time were 93.33%and 44.44%,respectively.The proportions of PLT≥50×109/L at least once after 9 months of treatment were 60.00%and 26.67%,respectively,and the attripopal group was higher than dexamethasone group(P<0.05).A comparison of the adverse reaction rate between aitopopal group and dexamethasone group(P>0.05).Conclusion Aitracopal can significantly reduce the risk of bleeding in patients with ITP,improve immune function,improve therapeutic effect,and high safety.
万方数据
维普
